Investors weren’t happy when Christophe Weber, the CEO of Japanese pharmaceuticals maker Takeda, said in March 2018 that he would pursue an expensive takeover of Irish rival Shire. Takeda has ...

10 years ago, Christophe Weber became the first non-Japanese CEO in Takeda Pharmaceuticals’ (NYSE:TAK) (TSE:4502) 242 year history. While Weber can point to a lengthy list of achievements over ...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years; Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process ...

When Christophe Weber was appointed CEO of Takeda in 2014, he set out on a mission to transform the 240-year old Japanese pharmaceutical company into a major global player.

Takeda CEO Christophe Weber spoke with Forbes about the Shire acquisition now that the deal has officially closed.

Christophe Weber sees Shire acquisition as key to growth. Back in 2013, Christophe Weber was offered a job as Takeda Pharmaceutical Co.’s chief operating officer, making him essentially the CEO ...

Although boss Christophe Weber will have plenty to celebrate on the upcoming fifth anniversary of his landmark $62 billion Shire acquisition, the deal has delivered no value to his shareholders.

Christophe Weber Thank you, Akama-san, for the second question, I will ask Iwasaki-san to answer because he is working on a daily, hour, minute, second basis on providing the vaccines to the Japanese.

Takeda Pharmaceuticals' new French-born CEO knows he is seen as an outsider by many Japanese, including some of Takeda's alumni. He appreciates their concerns and says Takeda will remain a ...